Streptococcal toxic shock syndrome in a returning traveller

References

• Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9(5):281–290.
   PubMed Web of Science ®Google Scholar
• Gottlieb M, Long B, Koyfman A. The evaluation and management of toxic shock syndrome in the emergency department: a review of the literature. J Emerg Med. 2018;54(6):807–814.
   PubMed Web of Science ®Google Scholar
• Davis JPCJ, Chesney PJ, Wand PJ, et al. Toxic-shock syndrome: epidemiologic feactures, recurrance, risk factors and prevention. N Engl J Med. 1980;303(25):1429–1435.
   PubMed Web of Science ®Google Scholar
• Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin Microbiol Rev. 2014;27(2):264–301.
   PubMed Web of Science ®Google Scholar
• Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of severe Streptococcus Pyogenes disease in Europe. J Clin Microbiol. 2008;46(7):2359–2367.
   PubMed Web of Science ®Google Scholar
• Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3(4):191–200.
   PubMed Web of Science ®Google Scholar
• McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Ann Rev Microbiol. 2001;55:77–104.
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A, Chatellier S, Low DE, et al. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol. 2000;30(11):3247–3255.
   PubMed Web of Science ®Google Scholar
• Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med. 2002;8(12):1398–1404.
   PubMed Web of Science ®Google Scholar
• Mascini EM, Jansze M, Schellekens JFP, et al. Invasive group A streptococcal disease in The Netherlands: evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis. 2000;181(2):631–638.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep. 1997;46(NoRR–10):33–34.
   PubMedGoogle Scholar
• Wilkins AL, Steer AC, Smeesters PR, et al. Toxic shock syndrome – the seven Rs of management and treatment. J Infect. 2017;74(suppl 1):S147–52.
   PubMedGoogle Scholar
• Dahl PR, Perniciaro C, Holmkvist KA, et al. Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J Am Acad Dermatol. 2002;47(4):489–492.
   PubMed Web of Science ®Google Scholar
• Ramos-e-Silva M, Libia Cardozo Pereira A. Life-threatening eruptions due to infectious agents. Clin Dermatol. 2005;23(2):148–156.
   PubMed Web of Science ®Google Scholar
• Karimi K, Odhav A, Kollipara R, et al. Acute cutaneous necrosis: a guide to early diagnosis and treatment. J Cutan Med Surg. 2017;21(5):425–437.
   PubMed Web of Science ®Google Scholar
• Colling ME, Bendapudi PK. Purpura fulminans: mechanism and management of dysregulated hemostasis. Transfus Med Rev. 2018;32(2):69–76.
   PubMed Web of Science ®Google Scholar
• Dhodapkar K, Corbacioglu S, Chang M. Purpura fulminans caused by group A ß-hemolytic Streptococcus sepsis. J Pediatr. 2000;134(4):562–567.
   Google Scholar
• Daskalaki MA, Boeckx WD, Demey A, et al. Toxic shock syndrome due to group A beta-hemolytic streptococcus presenting with purpura fulminans and limb ischemia in a pediatric patient treated with early microsurgical arteriolysis. J Pediatr Surg. 2013;48(1):2013.
   Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
   PubMed Web of Science ®Google Scholar
• Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive Group A Streptococcal infections. Clin Infect Dis. 2014;59(3):358–365.
   PubMed Web of Science ®Google Scholar
• Stevens D, Bisno A, Chambres H. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious disease society of America. Clin Infect Dis. 2014;59(2):e10–e52.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Swihart BJ, Bonne SL, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: A propensity score-matched analysis from 130 US hospitals. Clin Infect Dis. 2017;64(7):877–885.
   PubMed Web of Science ®Google Scholar
• Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333–340.
   PubMed Web of Science ®Google Scholar
• Provan D, Nokes TJC, Agrawal S, Winer J, Wood P, IVIg Guideline Development Group of the IVIg Expert Working Group. Clinical guidelines for immunoglobulin use. 2nd ed. London: Department of Health, 2008
   Google Scholar
• Kotlyar S, Rice B. Fever in the returning traveler. Emerg Med Clin North Am. 2013;31(4):927–944.
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, Schrooten W, Van den Enden E. Etiology and outcome of fever after a stay in the tropics. Arch Intern Med. 2006;166(15):1642–1648.
   PubMedGoogle Scholar